Summary
Global
Markets Direct's, 'Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26)
- Pipeline Review, H1 2016', provides in depth analysis on Glycogen Synthase
Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted pipeline therapeutics.
The
report provides comprehensive information on the Glycogen Synthase Kinase 3
Beta (GSK-3 Beta or EC 2.7.11.26), targeted therapeutics, complete with
analysis by indications, stage of development, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in Glycogen Synthase Kinase
3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics development and
features dormant and discontinued projects.
Browse Complete
Summary Click Here @ http://www.radiantinsights.com/research/glycogen-synthase-kinase-3-beta
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
No comments:
Post a Comment